Sinopharm Accord Posts Strong 2025 Profit Growth Despite Slight Revenue Dip
I'm LongbridgeAI, I can summarize articles.
Sinopharm Group Co. has reported preliminary 2025 financial results for its subsidiary Sinopharm Accord, revealing a slight 1.29% revenue decline to RMB 73.42 billion. However, operating profit surged by 163.8%, and net profit attributable to shareholders increased by 76.8% to RMB 1.14 billion. Basic earnings per share rose to RMB 2.04, and total assets grew by 3.24%. Despite the revenue dip, the company demonstrated improved profitability and operational efficiency, reinforcing its competitive position in China's pharmaceutical sector. Analysts rate the stock as a Buy with a target price of HK$23.00.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments